ADVERTISEMENT

If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.

It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.

Wiley InterScience


Journal of Cellular and Molecular Medicine

Journal of Cellular and Molecular Medicine

Volume 6 Issue 1, Pages 49 - 57

Published Online: 1 May 2007

© 2009 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd



< Previous Abstract  |  Next Abstract >

Save Article to My Profile      Download Citation      Request Permissions

Abstract |  References  |  Full Text: PDF (Size: 3658K)  | Related Articles | Citation Tracking

Myocardial changes after spironolactone in spontaneous hypertensive rats. A laser scanning confocal microscopy study1
Leila Maria Meirelles Pereira 1 C.A. Mandarim-de-Lacerda* 1
  1 Laboratory of Morphometry & Cardiovascular Morphology, Biomedical Centre, Institute of Biology, State University of Rio de Janeiro, Brazil
Correspondence to   *Mail to: Carlos Alberto MANDARIM-DE-LACERDA, MD, PhD Laboratório de Morfometria e Morfologia Cardiovascular, Centro Biomédico, Instituto de Biologia, Universidade do Estado do Rio de Janeiro, Av. 28 de Setembro, 87 (fds), 20551-030-Rio de Janeiro, RJ, Brasil. Tel/Fax: [+55.21] 2587-6416 Email: mandarim@uerj.br.Http://www2.uerj.br/~lmmc
 

1 Research supported by Brazilian agencies CNPq and FAPERJ

Copyright 2002 Blackwell Publishing Ltd.
KEYWORDS
spironolactone • enalapril • verapamil • hypertension • confocal microscopy

ABSTRACT

The present study aims to objectivate by laser scanning confocal microscopy, the cardiac structure of the spontaneously hypertensive rats (SHR) treated with different doses of spironolactone, either alone or in combination with an angiotensin converting enzyme inhibitor or with a calcium channel blocker. Thirty SHRs were divided into six groups and treated during 13 weeks as follows: control, spironolactone (5, 10 and 30 mg/kg/day), spironolactone + enalapril and spironolactone + verapamil. Spironolactone action on the SHR blood pressure (BP) was doses-dependent. The cardiac hypertrophy was affected by the treatment with spironolactone (high dose) or a combination of spironolactone and Enalapril. The myocardial structure was less affected by the spironolactone monotherapy (at all doses) showing hypertrophied cardiac myocytes, focal areas of the reactive fibrosis, inflammatory infiltrate. The treatment with spironolactone in combination with enalapril or verapmil prevented these alterations. In conclusion, the monotherapy with spironolactone had only a limited effect in the preservation of the myocardial structure and in the attenuation of the interstitial fibrosis in SHRs, even after high dose. This action on the myocardium is more efficient when the spironolactone (even in medium dose) was associated with enalapril or verapamil.


Received: December 28, 2001; Accepted: January 16, 2002

DIGITAL OBJECT IDENTIFIER (DOI)
10.1111/j.1582-4934.2002.tb00310.x About DOI

Related Articles

  • Find other articles like this in Wiley InterScience
  • Find articles in Wiley InterScience written by any of the authors

Wiley InterScience is a member of CrossRef.

Cross Ref Member


Sign Up Now
Sign Up Now
Asia Scientists Click Here
Sign up for Content Alerts